These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8004699)

  • 21. Effects of chroman derivatives on platelet aggregation induced by some aggregating agents in rabbits.
    Aida Y; Kasama T; Fukaya H; Takeuchi N; Sugiyama K; Tobinaga S
    Clin Exp Pharmacol Physiol; 1998 Nov; 25(11):939-44. PubMed ID: 9807668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma.
    Paris D; Cottin M; Demonchaux P; Augert G; Dupassieux P; Lenoir P; Peck MJ; Jasserand D
    J Med Chem; 1995 Feb; 38(4):669-85. PubMed ID: 7861415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor.
    Sawyer DA; Beams RM; Blackwell GJ; Brockwell MA; Cheesman NJ; Demaine DA; Garland LG; Hodson HF; Hyde RM; Islip PJ
    J Med Chem; 1995 Jun; 38(12):2130-7. PubMed ID: 7783144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
    Serradji N; Bensaid O; Martin M; Sallem W; Dereuddre-Bosquet N; Benmehdi H; Redeuilh C; Lamouri A; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):8109-25. PubMed ID: 16893650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.
    Sallem W; Serradji N; Dereuddre-Bosquet N; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):7999-8013. PubMed ID: 16908170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.
    Wissner A; Carroll ML; Green KE; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Wrenn S; Kohler CA
    J Med Chem; 1992 May; 35(9):1650-62. PubMed ID: 1578493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine.
    Kaminski JJ; Carruthers NI; Wong SC; Chan TM; Billah MM; Tozzi S; McPhail AT
    Bioorg Med Chem; 1999 Jul; 7(7):1413-23. PubMed ID: 10465415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
    Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
    J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
    J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antagonistic effects of khellactones on platelet-activating factor, histamine, and leukotriene D4.
    Aida Y; Kasama T; Takeuchi N; Tobinaga S
    Chem Pharm Bull (Tokyo); 1995 May; 43(5):859-67. PubMed ID: 7553972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids.
    Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Terashita Z; Sugihara H; Naka T
    Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):258-67. PubMed ID: 11253914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Derivatives of 2-methylenepropane-1,3-diol as new antagonists of platelet activating factor.
    Grue-Sørensen G; Nielsen IM; Nielsen CK
    J Med Chem; 1988 Jun; 31(6):1174-8. PubMed ID: 3373485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists.
    Carceller E; Merlos M; Giral M; Bartrolí J; García-Rafanell J; Forn J
    J Med Chem; 1992 Feb; 35(4):676-83. PubMed ID: 1542094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PAF-antagonists with phospholipid structure. 4. Alkylcarbamoylphospholipids with heteroarene and heterocyclase head groups and variation of the P-N-distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP; Schmidt B; Ostermann G
    Pharmazie; 1992 Mar; 47(3):172-4. PubMed ID: 1615020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH
    J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
    Lohde C; Bahr T; Labes D; Grupe R
    Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PAF-antagonists with phospholipid structure. 3. Phospholipids with heterocyclane head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationship].
    Kertscher HP; Ostermann G
    Pharmazie; 1991 Nov; 46(11):772-4. PubMed ID: 1811226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analogues of platelet activating factor. 4. Some modifications of the phosphocholine moiety.
    Wissner A; Schaub RE; Sum PE; Kohler CA; Goldstein BM
    J Med Chem; 1986 Mar; 29(3):328-33. PubMed ID: 3950913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.